ArticleCancer immunology, immunotherapy : CII2024

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.

Tanguy Y Seiwert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.